exercise considerations for the neuro-oncology patient
TRANSCRIPT
![Page 1: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/1.jpg)
Exercise Considerations For the Neuro-Oncology Patient
Frannie Westlake PT, DPTBoard Certified Neurologic and Oncologic Clinical Specialist
Oncology Rehab: Denver, CO
![Page 2: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/2.jpg)
Objectives
• Review Current Statistics of Brain Tumors in the US• Treatments for Brain Tumors and the Effect on Exercise• Discuss Current Methods of Exercise Prescription and Testing in the
Oncology Population• Review Current Guidelines for Exercise Interventions in the Oncology
Population
![Page 3: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/3.jpg)
![Page 4: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/4.jpg)
Benign Brain Tumors Malignant Brain Tumors
• Mass of cells that microscopically do not have the characteristic appearance of a cancer
• Found by CT or MRI brain scans
• Usually grow slowly
• Do not invade surrounding tissues or spread to other organs
• Often have a clear border or edge
• Not life threatening
• Brain tumors containing cancer cells
• More difficult to localize
• Often grow rapidly
• Invades and spreads to other organs
• Have no clear border or edge
• Life threatening ; Interfere with vital functions
www.abta.org
![Page 5: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/5.jpg)
![Page 6: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/6.jpg)
Metastatic Tumors
• A metastatic, or secondary, brain tumor is formed by cancer cells from a primary cancer elsewhere in the body that have spread to the brain
• Typically from:• Lung CA• Breast CA• Melanoma• Colon CA• Kidney CA
![Page 7: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/7.jpg)
Signs and Symptoms
• Increased intracranial pressure• Headache• Nausea• Vomiting• Decreased level of consciousness• 6th nerve palsy (one of the first CN to be compressed)
• Can be secondary to tumor mass, surrounding edema, or obstruction hydrocephalus
![Page 8: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/8.jpg)
Signs and Symptoms• Seizures
• Presenting symptom in 1/3 of all cases• Usually focal• Frontal lobe gliomas produce seizures in 60% of cases
• Altered Mental Status• Presenting in 20% of cases• Can range from subtle changes to severe problems• Can notice decreased LOC
![Page 9: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/9.jpg)
Signs and Symptoms
• Focal Neurological signs• Weakness – motor cortex (frontal)• Sensory loss – sensory cortex (parietal)• Speech disturbance (left frontal or temporal)• Visual (occipital)• Balance (cerebellum)• Vestibular deficits (cerebellum)
![Page 10: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/10.jpg)
Medical and Surgical Management
• Traditional surgery – craniotomy (partial or complete)• Chemotherapy• Radiation • Stereotactic Radiosurgery
![Page 11: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/11.jpg)
Chemotherapy
• Independent treatment or adjuvant to other types• Not effective for all types of tumors• Use of chemotherapeutic agents (combination preferred)• Mechanism: chemotherapeutic drugs arrest replication of cells, aim is
to stop division of cancer cells• Given in cycles: oral or intrathecal chemotherapy (into CSF)• Examples: Nitrosoureas (permeates BBB), methotrexate, Cisplatin
![Page 12: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/12.jpg)
Temodar
• Generic name: Temozolomide• Classified as alkylating agent
• It acts as “pro-drug” and needs to be transformed to its active form by the body’s metabolism
• Used for anaplastic astrocytoma and glioblastoma multiforme brain tumors• Given orally and recommended to take on an empty stomach• NADIR: 7-10 days; Recovery: 22-28 days
• Clinical Application/Patient Profiling: • Central Neurotoxicity – dizziness, balance problems, hemiparesis, seizures, excessive
sleepiness• Fatigue is also a common side effect
© PORi 12
![Page 13: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/13.jpg)
Avastin
• Classified as a “monoclonal antibody” and “anti-angiogenesis” drug• New type of targeted therapy• Inhibits human vascular endothelial growth factor (VEGF)• VEGF is a growth factor that leads to new blood vessel formation or angiogenesis
• Used to treat metastatic colon or rectal cancer, non-squamous non-small cell lung cancer, metastatic breast cancer, glioblastoma multiforme, metastatic renal cell carcinoma
• No NADIR information available• Clinical Application/Patient Profiling:
• Nose Bleeds• Diarrhea • Muscle weakness and joint pain
© PORi 13
![Page 14: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/14.jpg)
Side effects of Chemotherapy
• Destroys all rapid growing cells including• Hair follicles• Cells of digestive tract• Blood cells needed to fight infections• Results:
• Hair loss• Nausea/loss of appetite• Decreased immune system• Fatigue
![Page 15: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/15.jpg)
Chemotherapeutic drugs side effects
• Short-term and long term effects• Peripheral neuropathy• Paresthesias, numbness• Malaise, fatigue• Dizziness• Myelosuppresant – bone marrow suppression (decline in immunity,
anemia)• Muscle weakness
![Page 16: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/16.jpg)
Implications for PT
• Adjust treatment plan based on side effects• Consider patient’s participation in therapy
• Successful treatment plan is flexible
• Consider optimal time for therapy• Try to get baseline outcome measures if possible before starting
chemotherapy
![Page 17: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/17.jpg)
Radiation Therapy
• Independent treatment or adjuvant to other types• Treatment option for large tumors or inaccessible for surgical
resection• Profound metastasis may not be suitable for radiotherapy• Mechanism: ionizing radiations disrupt cell structure and stop growth• Types: external radiation (5 days/wk x several wks); Implant radiation
(loose radioactivity delivered each day)
![Page 18: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/18.jpg)
Side effects of Radiation
• Destruction of healthy cells• Loss of hair• Fatigue• Fibrosis• Cognitive deficits (learning problem in children)• Osteoporosis• Radiation necrosis
![Page 19: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/19.jpg)
Implications for PT
• Adjust treatment plan based on side effects• Consider patient’s participation in therapy• Consider optimal time for therapy• Irradiated areas should be protected from skin injury• No heat or cold agents or topical agents until skin damage is cleared
![Page 20: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/20.jpg)
Stereotactic Radiosurgery
• Delivery of a high dose of ionizing radiation, in a single fraction, to a small, precisely defined volume of tissue. A variety of machines used to produce the radiation:
• Gamma Knife• LINAC• Particle accelerator• CyberKnife
• Most beneficial for: centrally localized lesions (<3 cm); patients with increased surgical risk
![Page 21: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/21.jpg)
Optune Device
• Optune is a wearable, portable, FDA-approved device indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.
• Newly diagnosed GBM• If you have newly diagnosed GBM, Optune is used together with a chemotherapy called
temozolomide (TMZ) if:• Your cancer is confirmed by your healthcare professional AND• You have had surgery to remove as much of the tumor as possible
• Recurrent GBM• If your tumor has come back, Optune can be used alone as an alternative to standard medical
therapy if:• You have tried surgery and radiation and they did not work or are no longer working AND• You have tried chemotherapy and your GBM has been confirmed by your healthcare
professional
![Page 22: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/22.jpg)
![Page 23: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/23.jpg)
![Page 24: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/24.jpg)
![Page 25: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/25.jpg)
Craniotomy
• Either conventional or image guided• For tumor resection or for biopsy• Mandatory in large tumors presenting with ICP problems• Partial resection – malignant tumor; Complete resection – benign
tumor
![Page 26: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/26.jpg)
![Page 27: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/27.jpg)
Side effects of Craniotomy
• Prolonged general anesthesia• Extended hospital stay (infection)• Invasive technique: cerebral edema, cerebral damage, seizure
disorder• DVT, PE• Increased ICP in post-op period
![Page 28: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/28.jpg)
Implication for PT
• Aim is to mobilize patient• Positioning concerns in the acute post-op period• ICP concerns: avoid valsalva maneuver• Pain consideration
![Page 29: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/29.jpg)
A Cancer Population Specific VO2peak Assessment:
University of Northern Colorado Cancer
Rehabilitation Institute Multistage Treadmill Protocol
![Page 30: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/30.jpg)
VO2max
• Max volume of oxygen consumption (VO2max) is the best measure of overall heart function (Hayward et al., 2013)
• Establishing an accurate VO2max is critical to have for a cancer survivor (CS), as it allows Cancer Exercise Specialists to create an individualized exercise prescription
![Page 31: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/31.jpg)
VO2max
• VO2max is often achieved from a maximal treadmill test using gas analysis• Gas analysis is the MOST ACCURATE method of determining VO2max, but is expensive and not readily
available
• VO2peak is often used instead• Highest VO2 achieved during a test
• Doesn’t need gas analysis
• No cancer-specific treadmill protocol exists, so cancer survivors are forced to use apparently healthy protocols
![Page 32: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/32.jpg)
Bruce Treadmill ProtocolStage Time Speed % Grade
Warm-Up
2-3 Min. 1.7 0%
1 3 min. 1.7 10%
2 3 min. 2.5 12%
3 3 min. 3.4 14%
4 3 min. 4.2 16%
5 3 min. 5.0 18%
6 3 min. 5.5 20%
7 3 min. 6.0 22%
UNCCRI ProtocolStage Speed Grade Time0 1.0mph 0% 1 min1 1.5mph 0% 1 min2 2.0mph 0% 1 min3 2.5mph 0% 1 min4 2.5mph 2% 1 min5 3.0mph 2% 1 min6 3.3mph 3% 1 min7 3.4mph 4% 1 min8 3.5mph 5% 1 min9 3.6mph 6% 1 min10 3.7mph 7% 1 min11 3.8mph 8% 1 min12 3.9mph 9% 1 min13 4.0mph 10% 1 min14 4.1mph 11% 1 min15 4.2mph 12% 1 min16 4.3mph 13% 1 min17 4.4mph 14% 1 min18 4.5mph 15% 1 min19 4.6mph 16% 1 min20 4.7mph 17% 1 minCool-Down ** 0% *
![Page 33: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/33.jpg)
Statement of Purpose
• To assess the validity of the UNCCRI multi-stage treadmill protocol for a cancer-specific population against standard metabolic gas analysis and the Bruce treadmill protocol.
Four different values were compared
1. VO2peak obtained from UNCCRI Gas Analysis Protocol (UGA)
2. Estimated VO2peak calculated from the last completed stage of UGA using ACSM’s walking/running equations (UEV)
3. VO2peak from Bruce treadmill protocol (BTP)4. VO2peak calculated from UNCCRI without Gas Analysis Protocol (UNGA)
![Page 34: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/34.jpg)
Results
• No significant difference between UGA and UEV
• Significant difference between Bruce and UGA (p<0.05)
Bruce vs. UGA UEV vs. UGA
0
10
20
30
40
50
0 20 40
VO2p
eak
from
Bru
ce (m
L·kg
-1·
min
-1)
VO2peak via UGA (mL·kg-1·min-1)
0
10
20
30
40
50
0 10 20 30 40 50
UEV
(mL·
kg-1
·min
-1)
VO2peak via UGA (mL·kg-1·min-1)
A B
![Page 35: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/35.jpg)
Conclusion
• VO2peak did not significantly differ between UGA and UEV
• Gas analysis is not necessary
• VO2peak significantly differed between UGA and BTP
• BTP not accurate or suitable for cancer survivors
• UNGA treadmill time was significantly higher than UGA treadmill time
• Gas analysis equipment may actually hinder treadmill performance
• UNCCRI protocol is designed for CS’s suffering from cancer and treatment-related side effects
• Allows further progression and a higher, more accurate VO2peak
![Page 36: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/36.jpg)
Conclusion
The UNCCRI protocol provides patient comfort and a valid VO2peakvalue, and should be the standard VO2peak assessment for cancer
rehabilitation clinics and facilities.
![Page 37: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/37.jpg)
FITT Principle
Frequency
• Number of sessions per week• 3x/week of vigorous
activity (> 20 min/day)• 5x/week of moderate
activity (> 30 min/day; bout > 10 min)
Intensity
• Increase time before intensity• Always “triangulate”
with RPE
![Page 38: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/38.jpg)
FITT Principle
Time
• Total amount of time spent exercising or total caloric expenditure• Adjust to patient’s Fitness
level• Shorter periods, multiple
bouts, 3x/10 min/session• Goal: 1 x 30 min/session• Increase time before intensity
Type
• What is available?• What does the patient want to
do?• What is safe for the patient?• Aerobic, strength, and
flexibility training
![Page 39: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/39.jpg)
Phase Training Model
![Page 40: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/40.jpg)
Phases of Cancer Rehabilitation
• Who: Patients during treatment (chemotherapy and/or radiation)
• Goal: Attenuate the deleterious effects of chemotherapy and radiation treatment
• There may be no improvement of physiological parameters during this phase, but there should be little to no declination
• Exercise Training: Low intensity: 30-45% HRR and 1-RM; RPE of 1-3; 2/3 sessions per week
• Timeframe: During treatment or for up to three months
Phase 1:
![Page 41: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/41.jpg)
Phases of Cancer Rehabilitation
• Who: Patients graduating from Phase 1, or clients who have had surgical and/or hormonal treatment (no chemo/radiation)
• Goal: Build a foundational base using functional and corrective training
• Exercise Training: Low intensity: 40-60% HRR and 1-RM. Purpose is to incorporate foundational, technique-oriented exercises. Improvements should be seen in core strength, pelvic floor and shoulder girdle strength, ROM, and to progress from close-chained exercises to open-chained exercises. RPE of 3-6; 3 sessions per week
• Timeframe: 3 months
Phase 2:
![Page 42: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/42.jpg)
Phases of Cancer Rehabilitation
Phase 3:
• Who: Patients graduating from Phase 2 • Goal: Improve physiological and psychological values
beyond baseline. Improvements should be seen in cardiovascular fitness, pulmonary function, muscular strength and endurance, balance, and flexibility. Psychological improvements should be visible e.g. QOL, Fatigue, and Depression
• Patients should be back to functional health or “apparently healthy”
• Exercise Training: Moderate-to-high intensity: 60-85% HRR and 1-RM; RPE of 4-8, 3 sessions per week
• Timeframe: 3 months
![Page 43: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/43.jpg)
Phases of Cancer RehabilitationPhase 3:
• Continued: Phase 3 marks the end of true cancer rehabilitation, therefore a primary focus should be to encourage clients to build intrinsic motivation and self-efficacy with exercise
• Patients need to learn proper form and how to develop their own exercise intervention
![Page 44: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/44.jpg)
Phases of Cancer Rehabilitation
• Who: Patients graduating from Phase 3• Goal: Continue improving in physiological and
psychological parameters. Improvements should be seen linearly during training.
• Exercise Training: Moderate-to-high intensity: 65-95% HRR and 1-RM; RPE of 6-10, 3 or more sessions per week. Interval training, group fitness, and open gym training is appropriate
• Timeframe: Limitless
Phase 4:
![Page 45: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/45.jpg)
Updated ACSM Guidelines
45
![Page 46: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/46.jpg)
Exercise is Medicine (2019)
46
![Page 47: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/47.jpg)
47
![Page 48: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/48.jpg)
Questions???
![Page 49: Exercise Considerations For the Neuro-Oncology Patient](https://reader030.vdocuments.mx/reader030/viewer/2022012804/61bd2a6d61276e740b10069c/html5/thumbnails/49.jpg)
References• Daniel Yoon Kee Shackelford, Jessica Marlene Brown, Brent Michael Peterson, Jay Schaffer,
Reid Hayward, The University of Northern Colorado Cancer Rehabilitation Institute Treadmill Protocol Accurately Measures Vo2 Peak in Cancer Survivors, International Journal of Physical Medicine and Rehabilitation, Volume 5 Issue 6, 2017
• Jessica Marlene Brown, Daniel Yoon Kee Shackelford, Maria Lynn Hipp, Reid Hayward, Evaluation of an Exercise-Based Phase Program as Part of a Standard Care Model for Cancer Survivors, Translational Journal of the ACSM, Volume 4, Number 7, 2019
• Kristin L Campbell, Kerri M. Winters-Stone, Joachim Wiskemann, Anne M. May et al, Exercise Guidelines for Cancer Survivors: Consensus Statement from InternationalMultidisciplinary Roundtable, Medicine and Science in Sports and Exercise, 2019
• Quinn T Ostrom, Gino Cioffi, Haley Gittleman, Nirav Patil, Kristin Waite, Carol Kruchko, Jill S Barnholtz-Sloan, CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016, Neuro-Oncology, Volume 21, Issue Supplement_5, October 2019, Pages v1–v100.
• www,abta.org• www.cancer.org